About
Mantra Bio is developing next generation, targeted therapeutics based on its proprietary exosome engineering platform, REVEAL™. The REVEAL™ platform, which integrates computational biology and bench lab automation, leverages the diversity of exosomes to enable the rational design of therapeutics directed at a wide range of tissue and cellular targets. Mantra Bio has also established a scalable biomanufacturing process and related technologies to ensure this new class of therapeutics can be reproducibly made at high purity, consistency, and yield. The company's initial pipeline includes engineered exosome therapeutics in the areas of ophthalmology and infectious diseases. Investors include 8VC, Viking Global Investors, Samsung Securities, BoxGroup, Allen & Company LLC, and Illumina. Learn more about Mantra Bio at www.mantrabio.com
San FranciscoTherapeuticsArtificial IntelligenceBiotechnologyManufacturing